# James K. Min

> James K. Min is the founder and CEO of Cleerly, a Denver-based digital health company using AI to analyze coronary CT scans and detect atherosclerosis long before a heart attack strikes. A board-certified cardiologist who spent two decades in academic medicine, Min left a professorship at Weill Cornell and the directorship of the Dalio Institute of Cardiovascular Imaging to build a company that could deliver personalized, plaque-based heart evaluation at scale. He has authored more than 500 peer-reviewed papers, led landmark cardiac imaging trials, and raised hundreds of millions to push a shift from population-based cardiology toward individualized care.

- **Role:** Founder and CEO at Cleerly
- **Organizations:** Cleerly, Society of Cardiovascular Computed Tomography (former), Weill Cornell Medical College (former), Dalio Institute of Cardiovascular Imaging (former)
- **From:** Norman, Oklahoma, United States
- **Nationality:** American
- **Education:** Bachelor of Arts, University of Chicago, Doctor of Medicine (MD), Temple University School of Medicine, Internship, residency in medicine, and cardiovascular medicine fellowship, University of Chicago Hospitals
- **Known for:** Founded and leads Cleerly, an FDA-cleared AI platform for coronary artery disease analysis, Authored more than 500 peer-reviewed manuscripts on cardiac CT and coronary artery disease, Principal Investigator on landmark trials including ACCURACY, CONFIRM, CONSERVE, CREDENCE, ICONIC and PARADIGM

## Career timeline

- **2005-2011** — Assistant professor of medicine and radiology at Weill Cornell Medical College, New York
- **2010-2013** — Senior investigator at Harvard Clinical Research Institute, Boston
- **2011-2013** — Associate professor of biomedical sciences, imaging and medicine at Cedars-Sinai Medical Center, Los Angeles
- **2013-2017** — Professor of radiology and medicine at NewYork-Presbyterian/Weill Cornell; founder and director of the Dalio Institute of Cardiovascular Imaging
- **2017** — Founded Cleerly to bring AI-based coronary plaque analysis to scale
- **2021** — Cleerly raised $43 million; FDA clearances for its coronary analysis software
- **2022** — Cleerly closed a $223 million Series C led by T. Rowe Price and Fidelity
- **2024** — Cleerly raised a $106 million Series C extension led by Insight Partners; secured Medicare coverage and a CPT Category I code

## Achievements

- Founded and leads Cleerly, an FDA-cleared AI platform for coronary artery disease analysis
- Authored more than 500 peer-reviewed manuscripts on cardiac CT and coronary artery disease
- Principal Investigator on landmark trials including ACCURACY, CONFIRM, CONSERVE, CREDENCE, ICONIC and PARADIGM
- Led the CONFIRM registry spanning 30,000+ patients across multiple countries
- Past President of the Society of Cardiovascular Computed Tomography (SCCT)
- 2017 recipient of the SCCT Gold Medal Award
- Former Editor-in-Chief of the Journal of Cardiovascular Computed Tomography
- Founding director of the Dalio Institute of Cardiovascular Imaging, backed by a $20M gift from Ray Dalio
- Raised more than $400 million in total funding for Cleerly

## Latest updates

- **2024-12** — Cleerly raised a $106 million Series C extension led by Insight Partners with Battery Ventures, following Medicare coverage and a CPT Category I code for advanced plaque analysis.
- **2025-02** — Min featured discussing the future of cardiac care using advanced plaque analysis in Cardiovascular Business coverage.

## Links

- Website: https://cleerlyhealth.com
- LinkedIn: http://www.linkedin.com/in/jameskminmd
- Twitter/X: https://twitter.com/cleerly_inc
- YouTube: https://www.youtube.com/watch?v=hsca072c9X4
- Facebook: https://facebook.com/cleerlyhealth

---

Profile page: https://yespress.io/james-min
Published by YesPress — https://yespress.io
Last updated: 2026-07-16